Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.27 -2.08%

-$0.10 today

Market cap
$1.53B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.27M

Average 4.72M

PGEN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Precigen, Inc.NASDAQ: PGEN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $7.28M fell 36.6% year over year, behind the -30.0% change in trailing-twelve-month research & development. Sequentially, it rose 36.9% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.

Context

  • Research & development amounted to 413.7% of revenue in FY2025, down 938.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -36.6% toward the trailing-twelve-month pace of -30.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$7.28M+36.9% QoQ
Last fiscal yearDec 2025
$40.06M-24.5% YoY
LTMJun 2026
$31.33M-30.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.6%——
1 year-24.5%——
3-year CAGR-5.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
40.06M USD
Year-over-year change
-24.5%
4-year CAGR
-4.4%

Research & Development vs competitors

How PGEN compares with its peers on the latest reported figures

  • PGEN's LTM Jun 2026 research & development of $31.33M is the 7th highest of the 8 companies compared; the peer median is $137.53M.
  • Its year-over-year change of -30.0% is the 7th highest of 8, against a peer median of -14.3%.
  • Research & development amounts to 36.6% of revenue for PGEN, versus a peer median of 221.0%.
PGEN Competitors Peer median
Research & Development for PGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M -21.5%-2.5%546.5%
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M +1.6%-16.9%1125.4%
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M +12.8%-2.0%260.4%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$137.53M -14.3%-5.0%—
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M -62.3%-19.9%171.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M -10.8%+5.5%118.4%
PGENPrecigen, Inc.LTM Jun 2026$31.33M -30.0%-5.3%36.6%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$26.43M -28.8%-2.5%181.7%
Peer median (excluding PGEN) $137.53M-14.3%-2.5%221.0%

Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.27M26.91M6.23M3.93M9.68M
Cost of Revenue53.68M6.34M6.12M4.27M6.1M
Gross Profit(39.41M)20.57M106K(342K)3.59M
Gross Margin-276.2%76.4%1.7%-8.7%37.1%
Research & Development47.93M47.17M48.61M53.07M40.06M
Selling, General & Admin048.01M40.42M41.29M70.13M
Operating Expenses52.54M96.3M99.86M134.69M110.19M
Depreciation & Amortization13.76M10.77M6.67M4.53M3.2M
EBITDA(77.64M)(62.43M)(89.23M)(123.5M)(243.57M)
EBITDA Margin-544.2%-232.0%-1433.3%-3146.4%-2515.2%
Operating Income(91.95M)(75.73M)(99.76M)(135.03M)(106.6M)
Operating Margin-644.5%-281.4%-1602.5%-3440.2%-1100.8%
Interest Income171K133K3.24M1.42M3.22M
Interest Expense18.76M6.77M468K6K3.87M
Other Income / Expenses(19.02M)(4.24M)3.4M7M(144.04M)
Income Before Tax(110.97M)(79.97M)(96.36M)(128.03M)(250.64M)
Pre-Tax Margin-777.8%-297.2%-1548.0%-3261.9%-2588.2%
Income Tax Expense(160K)(189K)(458K)(1.79M)3K
Net Income(92.17M)28.32M(95.9M)(126.24M)(250.64M)
Net Margin-646.0%105.2%-1540.6%-3216.2%-2588.2%
EPS (Basic)(0.47)(0.33)(0.39)(0.47)(1.41)
EPS (Diluted)(0.47)(0.40)(0.39)(0.47)(1.41)
Weighted Avg Shares197.76M200.36M244.54M267.73M304.71M
Weighted Avg Shares (Diluted)197.76M200.36M244.54M267.73M304.71M

Precigen, Inc.

NASDAQ:PGEN

Intrinsic Alpha fair value

Locked

Current Price

$4.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.